Genomic characterisation of a novel KPC-98-producing clinical Klebsiella pneumoniae strain conferring resistance to ceftazidime/avibactam

Mendes, Gabriel; Santos, Maria Leonor; Ramalho, João Francisco; Bruschy-Fonseca, Ana; Lito, Luís; Pedro, Diogo; Duarte, Aida; Cristino, José Melo; Caneiras, Catia

http://hdl.handle.net/10451/61161

Utilize este identificador para referenciar este registo.

Nome:	Descrição:	Tamanho:	Formato:
Genomic_KPC98.pdf		612.91 KB	Adobe PDF	Ver/Abrir

Contacte-nos

Autores

Mendes, Gabriel

Santos, Maria Leonor

Ramalho, João Francisco

Resumo(s)

Ceftazidime/avibactam (CZA) is a novel drug that inactivates Ambler class A, including Klebsiella pneumoniae carbapenemases (KPC), class C and class D β-lactamases, but is not active against metallo-β-lactamases (class B). Despite its limited use worldwide, emerging cases of CZA-resistant isolates producing variants of the blaKPC gene have been reported. In this study, we report a novel KPC-98 variant conferring CZA resistance identified in a highly virulent and multidrug-resistant clinical isolate of K. pneumoniae, belonging to the high-risk international clone sequence type 13 (ST13).